Analyst Price Targets — FDMT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 11, 2025 10:23 am | Gena Wang | Barclays | $33.00 | $10.17 | TheFly | 4D Molecular price target lowered to $33 from $38 at Barclays |
| October 31, 2025 1:20 pm | Mani Foroohar | Leerink Partners | $17.00 | $11.50 | StreetInsider | 4D Molecular Therapeutics (FDMT) PT Raised to $17 at Leerink Partners |
| October 21, 2025 1:11 pm | Lisa Walter | RBC Capital | $26.00 | $10.77 | StreetInsider | RBC Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT) |
| January 11, 2025 7:38 pm | Judah Frommer | Morgan Stanley | $6.00 | $5.52 | TheFly | 4D Molecular price target lowered to $6 from $8 at Morgan Stanley |
| September 19, 2024 8:14 am | Kostas Biliouris | BMO Capital | $40.00 | $13.28 | StreetInsider | BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT) |
| September 19, 2024 8:06 am | Geulah Livshits | Loop Capital Markets | $39.00 | $13.31 | StreetInsider | Chardan Capital Markets Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT) |
| September 19, 2024 6:46 am | Matthew Caufield | H.C. Wainwright | $36.00 | $13.31 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT) |
| April 15, 2024 6:29 am | Lisa Walter | RBC Capital | $40.00 | $26.35 | StreetInsider | 4D Molecular Therapeutics (FDMT) PT Raised to $40 at RBC Capital |
| April 15, 2024 3:43 am | Gena Wang | Barclays | $45.00 | $26.35 | StreetInsider | Barclays Starts 4D Molecular Therapeutics (FDMT) at Overweight |
| April 1, 2024 7:51 am | Nalin Tejavibulya | Jefferies | $58.00 | $31.86 | StreetInsider | 4D Molecular Therapeutics (FDMT) PT Raised to $58 at Jefferies on multiple catalysts in 2024 |
Latest News for FDMT
EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor…
EMERYVILLE, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on February 10, 2026, the compensation committee of the Company's board of directors…
Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections 4FRONT-1 overenrolled and expected to exceed 500 patients randomized, reflecting strong interest from investigators and patients Topline data from 4FRONT-1 expected in H1 2027 4FRONT-2 global site activation momentum continues, with enrollment completion…
EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026, the compensation committee of the Company's board of directors…
4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for FDMT.
U.S. House Trading
No House trades found for FDMT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.